Abstract
Ensuring the correct use of genetic tests is an important challenge for health-policy makers. Many new genetic tests will identify susceptibility to common diseases or adverse drug responses. Some will lead to new prevention opportunities, but others will have minimal clinical value. Statutory regulation alone cannot guarantee appropriate use. Other strategies, including resource allocation and matters related to clinical governance — such as practice-guideline development and health-provider education — are also important.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Progress along developmental tracks for electronic health records implementation in the United States
Health Research Policy and Systems Open Access 16 March 2009
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Collins, F. S. Shattuck lecture — medical and societal consequences of the Human Genome Project. N. Engl. J. Med. 341, 28–37 (1999).
Roses, A. D. Pharmacogenetics and the practice of medicine. Nature 405, 857–865 (2000).
Holtzman, N. A. & Watson, M. S. Promoting Safe and Effective Genetic Testing in the United States. Final Report of the Task Force on Genetic Testing (Johns Hopkins, Baltimore, 1999).
Godard, B., ten Kate, L., Evers-Kiebooms, G. & Ayme, S. Population genetic screening programmes: principles, techniques, practices, and policies. Eur. J. Hum. Genet. 11 (Suppl. 2), 49–87 (2003).
Reich, L. M., Bower, M. & Key, N. S. Role of the geneticist in testing and counseling for inherited thrombophilia. Genet. Med. 5, 133–143 (2003).
Juul, K., Tybyaerg-Hansen, A., Schnohr, P. & Nordestgaard, B. G. Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. Ann. Intern. Med. 140, 330–337 (2004).
Humphries, S. E., Ridker, P. M. & Talmud, P. J. Genetic testing for cardiovascular disease susceptibility: a useful clinical management tool or possible misinformation? Arterioscler. Thromb. Vasc. Biol. 24, 628–636 (2004).
Marteau, T. M. & Lerman, C. Genetic risk and behavioural change. BMJ 322, 1056–1059 (2001).
Mayeux, R. & Schupf, N. Apolipoprotein E and Alzheimer's disease: the implications of progress in molecular medicine. Am. J. Public Health 85, 1280–1284 (1995).
Patten, S., Barton, D. & Elles, R. Retaining the confidence of the public in molecular genetic testing. Commun. Genet. 3, 164–169 (2000).
Ibarratta, D., Bock, A. K., Klein, C. & Rodriguez-Cerezo E. Towards quality assurance and harmonization of genetic testing services in Europe: current practices and issues, <http://esto.jrc.es/detailshort.cfm?ID_report=1124> (2003).
Centers for Medicare & Medicaid Services CLIA program: Clinical Laboratory Improvement Amendments, <http://www.cms.hhs.gov/clia/> (2004).
Secretary's Advisory Committee on Genetic Testing. Enhancing the oversight of genetic tests: recommendations of the SACGT, <http://www4.od.nih.gov/oba/sacgt/reports/oversight_report.pdf> (National Institutes of Health, July, 2000).
Secretary's Advisory Committee on Genetic Testing. Thirteenth meeting, <http://www4.od.nih.gov/oba/sacgt/transcript5-14-02.pdf> and <http://www4.od.nih.gov/oba/sacgt/transcript5-15-02.pdf> (14 and 15 May, 2002).
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research & Center for Devices and Radiological Health. Guidance for industry: pharmacogenomic data submissions, <http://www.fda.gov/cder/guidance/5900dft.pdf> (November, 2003).
Tabloid Prescribing information, <http://www.fda.gov/medwatch/SAFETY/2003/03DEC_PI/Tabloid_PI.pdf> (2003).
UK Human Genetics Commission. Genes direct: ensuring the effective oversight of genetic tests supplied directly to the public, <http://www.hgc.gov.uk/genesdirect/> (2003).
US General Accounting Office. Prescription drugs: FDA oversight of direct to consumer advertising has limitations, <http://www.gao.gov/atext/d03177.txt> (2003).
Specter, M. Miracle in a bottle. New Yorker 64–75 (2 Feb 2004).
McGleenan, T. Legal and policy issues in genetics and insurance. Commun. Genet. 3, 45–49 (2000).
Godard, B. et al. Genetic information and testing in insurance and employment: technical, social and ethical issues. Eur. J. Hum. Genet. 11 (Suppl. 2), 123–142 (2003).
Hall, M. A. & Rich, S. S. Laws restricting health insurers' use of genetic information: impact on genetic discrimination. Am. J. Hum. Genet. 66, 293–307 (2000).
UK Human Genetics Commission. Inside information: balancing interests in the use of personal and genetic data, <http://www.hgc.gov.uk/insideinformation/> (2003).
Institute of Medicine. Guidelines for Clinical Practice: from Development to Use (National Academy Press, Washington DC, 1992).
Woolf, S. H. Evidence-based medicine and practice guidelines: an overview. Cancer Control 7, 362–367 (2000).
Miller, J. & Petrie, J. Development of practice guidelines. Lancet 355, 82–83 (2000).
Childs, B. & Valle, D. Genetics, biology and disease. Annu. Rev. Genomics Hum Genet. 1, 1–19 (2000).
Wilcken, B. Rare diseases and the assessment of intervention: what sorts of clinical trials can we use? J. Inherit. Metab. Dis. 24, 291–298 (2001).
Brandi, M. L. et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 86, 5658–5671 (2001).
US Preventive Services Task Force. Guide to clinical preventive services (Williams & Wilkins, Baltimore, Maryland, 1996).
Davies, S. C. et al. Screening for sickle cell disease and thalassaemia: a systematic review with supplementary research. Health Technol. Assess. 4, 1–99 (2000).
Zeuner, D. et al. Antenatal and neonatal haemoglobinopathy screening in the UK: review and economic analysis. Health Technol. Assess. 3, 1–186 (1999).
Press, R. D., Bauer, K. A., Kujovich, J. L. & Heit, J. A. Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch. Pathol. Lab. Med. 126, 1304–1318 (2002).
Grody, W. W., Griffin, J. H., Taylor, A. K., Korf, B. R. & Heit, J. A. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet. Med. 3, 139–148 (2001).
Holtzman, N. A. & Marteau, T. M. Will genetics revolutionize medicine? N. Engl. J. Med. 343, 141–144 (2000).
Nebert, D. W., Jorge-Nebert, L. & Vesell, E. S. Pharmacogenomics and “individualized drug therapy”: high expectations and disappointing achievements. Am. J. Pharmacogenomics 3, 361–370 (2003).
Burke, W. & Emery, J. Genetics education for primary-care providers. Nature Rev. Genet. 3, 561–566 (2002).
Godard, B. et al. Provision of genetic services in Europe: current practices and issues. Eur. J. Hum. Genet. 11 (Suppl. 2), 13–48 (2003).
National Coalition for Health Professional Education in Genetics. Preparing health professionals for the genomics revolution, <http://www.nchpeg.org/> (2004).
Burton, H., Shuttleworth, A. & Metcalfe, A. Genetics education for nurses, midwives and health visitors. Prof. Nurse 18, 676–680 (2003).
Ramsey, S. Economic analyses and clinical practice guidelines: why not a match made in heaven. J. Gen. Intern. Med. 17, 235–237 (2002).
Acknowledgements
This work was supported in part by the US National Human Genome Research Institute (W.B.). The Public Health Genetics Unit is funded by the UK Departments of Health and the Wellcome Trust. The views expressed are those of the authors and do not necessarily reflect the views or positions of the authors' affiliations.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Glossary
- ANALYTIC VALIDITY
-
The accuracy with which a particular genetic characteristic — such as a DNA sequence variant, chromosomal deletion or biochemical indicator — can be identified in a given laboratory test.
- CLINICAL UTILITY
-
The risks and benefits resulting from test use.
- CLINICAL VALIDITY
-
The accuracy with which a test identifies or predicts a patient's clinical status.
- PERSONALIZED MEDICINE
-
The use of genetic susceptibility or pharmacogenetic testing to tailor an individual's preventive care or drug therapy.
- PHARMACOGENETICS
-
The study of drug responses related to inherited genetic differences.
- PHENYLKETONURIA
-
A genetic condition resulting in the inability to metabolize normal amounts of the amino acid phenylalanine. Mental retardation occurs if the condition is untreated, but can be prevented by the initiation of a phenylalanine-restricted diet in the newborn period.
- THIOGUANIONE
-
An anti-metabolite medication used to treat some kinds of cancer.
Rights and permissions
About this article
Cite this article
Burke, W., Zimmern, R. Ensuring the appropriate use of genetic tests. Nat Rev Genet 5, 955–959 (2004). https://doi.org/10.1038/nrg1495
Issue Date:
DOI: https://doi.org/10.1038/nrg1495
This article is cited by
-
Issues concerning the evaluation and regulation of predictive genetic testing
Journal of Community Genetics (2014)
-
Usefulness of factor V Leiden mutation testing in clinical practice
European Journal of Human Genetics (2010)
-
Progress along developmental tracks for electronic health records implementation in the United States
Health Research Policy and Systems (2009)
-
Public Health Genomics
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz (2009)
-
Scientific rationality, uncertainty and the governance of human genetics: an interview study with researchers at deCODE genetics
European Journal of Human Genetics (2006)